For more than four decades, Fenwick & West LLP has helped some of the world’s most recognized companies become, and remain, market leaders. From emerging enterprises to large public corporations, our clients are leaders in the technology, life sciences and cleantech sectors and are fundamentally changing the world through rapid innovation.  MORE >

Fenwick & West was founded in 1972 in the heart of Silicon Valley—before “Silicon Valley” existed—by four visionary lawyers who left a top-tier New York law firm to pursue their shared belief that technology would revolutionize the business world and to pioneer the legal work for those technological innovations. In order to be most effective, they decided they needed to move to a location close to primary research and technology development. These four attorneys opened their first office in downtown Palo Alto, and Fenwick became one of the first technology law firms in the world.  MORE >

From our founding in 1972, Fenwick has been committed to promoting diversity and inclusion both within our firm and throughout the legal profession. For almost four decades, the firm has actively promoted an open and inclusive work environment and committed significant resources towards improving our diversity efforts at every level.  MORE >

FLEX by Fenwick is the only service created by an AmLaw 100 firm that provides flexible and cost-effective solutions for interim in-house legal needs to high-growth companies.  MORE >

Fenwick & West handles significant cross-border legal and business issues for a wide range of technology and life sciences who operate internationally..  MORE >

At Fenwick, we are proud of our commitment to the community and to our culture of making a difference in the lives of individuals and organizations in the communities where we live and work. We recognize that providing legal services is not only an essential part of our professional responsibility, but also an excellent opportunity for our attorneys to gain valuable practical experience, learn new areas of the law and contribute to the community.  MORE >

Year after year, Fenwick & West is honored for excellence in the legal profession. Many of our attorneys are recognized as leaders in their respective fields, and our Corporate, Tax, Litigation and Intellectual Property Practice Groups consistently receive top national and international rankings, including:

  • Named Technology Group of the Year by Law360
  • Ranked #1 in the Americas for number of technology deals in 2015 by Mergermarket
  • Nearly 20 percent of Fenwick partners are ranked by Chambers
  • Consistently ranked among the top 10 law firms in the U.S. for diversity
  • Recognized as having top mentoring and pro bono programs by Euromoney


We take sustainability very seriously at Fenwick. Like many of our clients, we are adopting policies that reduce consumption and waste, and improve efficiency. By using technologies developed by a number of our cleantech clients, we are at the forefront of implementing sustainable policies and practices that minimize environmental impact. In fact, Fenwick has earned recognition in several areas as one of the top US law firms for implementing sustainable business practices.  MORE >

At Fenwick, we have a passion for excellence and innovation that mirrors our client base. Our firm is making revolutionary changes to the practice of law through substantial investments in proprietary technology tools and processes—allowing us to deliver best-in-class legal services more effectively.   MORE >

Mountain View Office
Silicon Valley Center
801 California Street
Mountain View, CA 94041

San Francisco Office
555 California Street
12th Floor
San Francisco, CA 94104

Seattle Office
1191 Second Avenue
10th Floor
Seattle, WA 98101

New York Office
1211 Avenue of the Americas
32nd Floor
New York, NY 10036

Shanghai Office
Unit 908, 9/F, Kerry Parkside Office
No. 1155 Fang Dian Road
Pudong New Area, Shanghai 201204
P.R. China
+86 21 8017 1200

Ewa M. Davison, Ph.D.

Associate, Litigation  

Seattle 206.389.4564


Ewa Davison, Ph.D., focuses her practice on litigating patent matters for companies in the life sciences, biotechnology, pharmaceutical and chemistry arenas. Ewa’s experience includes resolving disputes in the federal district courts and the Court of Appeals for the Federal Circuit, in addition to her growing inter partes review (IPR) practice.

Ewa was selected as a Washington “Rising Star” in the area of Intellectual Property Litigation in 2016 and 2015, and recently completed a trial fellowship with the King County Prosecutor’s Office. She served as a managing editor of the Washington Law Review while in law school. At MIT, she worked in the laboratory of Dr. H. Robert Horvitz, winner of the 2002 Nobel Prize in Physiology or Medicine. Ewa was awarded several academic distinctions while an undergraduate at Princeton University.

Prior to joining Fenwick & West, Ewa clerked for the Honorable Richard C. Tallman of the Ninth Circuit Court of Appeals.

Legal Publications

  • Armen N. Nercessian and Ewa M. Davison, Litigation Alert: Supreme Court Extends Petrella Rule Barring Laches to Patent Context, March 2017.
  • Ewa M. Davison and Amy E. Hayden, Biosimilars: Solicitor General Recommends Granting Certiorari in Amgen v. Sandoz, Life Sciences Legal Insights Blog, December 2016.
  • Amy E. Hayden and Ewa M. Davison, Will the Supreme Court Review Whether FDA-Mandated Bioequivalence Testing to Maintain Approval Falls Within the § 271(e)(1) Safe Harbor?, Life Sciences Legal Insights Blog, August 2016.
  • Amy E. Hayden, Ewa M. Davison and David Tellekson, Federal Circuit: A Biosimilar Applicant Must Provide Notice of Intent to Market a Biosimilar Product, No Exceptions, Life Sciences Legal Insights Blog, July 2016.
  • Amy E. Hayden, Ewa M. Davison, and David K. Tellekson, Litigation Alert: No Exception to Statutory Requirement that a Biosimilar Applicant Provide Notice of Intent to Market its Product, July 2016.
  • Adam Lewin and Ewa M. Davison, Federal Circuit clarifies the 'on-sale bar.' (The Medicines Co. v. Hospira, Inc.), The Los Angeles Daily Journal, July 2016.
  • Amy E. Hayden, Ewa M. Davison and David K. Tellekson, The Amgen Quagmire: Federal Circuit Rules Patent Dance Does Not Excuse Biosimilar Applicants from Providing Notice of Intent to Market, IPWatchdog, July 2016.
  • Jeffrey Ware, Ewa M. Davison and David K. Tellekson, Supreme Court Refuses to Put the Brakes on PTAB, The Recorder, June 2016.
  • Amy E. Hayden, Ewa M. Davison and David K. Tellekson, Biosimilars: Supreme Court Calls for Solicitor General’s vVews in Amgen v. Sandoz, June 2016.
  • Jeffrey Ware, Ewa M. Davison, and David Tellekson, Litigation Alert: Supreme Court Leaves Intact PTAB Authority to Institute and Regulate Inter Partes Review Proceedings, June 2016.
  • Adam Lewin, Ewa M. Davison and Bryan Kohm, Biotech companies turn to ITC forum. (International Trade Commission), The Los Angeles Daily Journal, April 2016.
  • Ewa M. Davison and David Tellekson, Riddle Me This: The Federal Circuit Provides a Measure of Clarity to the Enigmatic Biosimilar Approval Pathway, August 11, 2015.
  • Ewa M. Davison and David K. Tellekson, Murky Waters: Post-Approval Regulatory Activities and the § 271(e)(1) Safe Harbor, Intellectual Property Bulletin, Winter 2013.
  • Ewa M. Davison, Melanie L. Mayer and Stuart P. Meyer, Final Patent Rules Provide Few Surprises, Intellectual Property Bulletin, Summer 2012.
  • Stuart P. Meyer, Ewa M. Davison and Melanie L. Mayer, IP Litigation Alert: PTO Publishes Final Rules for Contested Patent Cases, August 2012.
  • David K. Tellekson and Ewa M. Davison, Litigation Alert: Supreme Court Leaves Intact PTAB Authority To Institute And Regulate Inter Partes Review Proceedings, June 2012.
  • David K. Tellekson and Ewa M. Davison, Supreme Court Allows Generic Manufacturers To Challenge Overbroad Use Codes, Intellectual Property Bulletin, Spring 2012.
  • Heather N. Mewes, David Tellekson and Ewa M. Davison, Patent Litigation Alert: Supreme Court Allows Generic Manufacturers to Challenge Overbroad Use Codes, April 2012.
  • Ewa M. Davison and David K. Tellekson, California Supreme Court to Hear Cipro “Pay-for-Delay” Case, February 2012.
  • Steve P. Calandrillo and Ewa M. Davison, The Dangers of the Digital Millennium Copyright Act: Much Ado About Nothing?, 50 Wm. & Mary L. Rev. 349 (2008).
  • Ewa M. Davison & Gary M. Myles, How Biotech Patentees Can Navigate KSR, Managing Intellectual Property, July/August 2008, at 79.
  • Ewa M. Davison, Enjoys Long Walks on the Beach: Washington’s Public Trust Doctrine and the Right of Pedestrian Passage over Private Tidelands, 81 Wash. L. Rev. 813 (2006).​

Scientific Publications

  • Davison, E.M., Saffer, A.M., Huang, L.S., DeModena, J., Sternberg, P.W., and Horvitz, H.R. (2011). The LIN-15A and LIN-56 Transcriptional Regulators Interact to Negatively Regulate EGF/Ras Signaling in Caenorhabditis elegans Vulval Cell-Fate Determination. Genetics 187, 803-815.
  • Davison, E.M., Harrison, M.M., Walhout, A.J.M., Vidal, M., and Horvitz, H.R. (2005). lin-8, which antagonizes C. elegans Ras-mediated vulval induction, encodes a novel nuclear protein that interacts with the LIN-35 Rb protein. Genetics 171, 1017–1031.
  • Bollag, R.J., Siegfried, Z., Cebra-Thomas, J.A., Garvey, N., Davison, E.M., and Silver, L.M. (1994). An ancient family of embryonically expressed mouse genes sharing a conserved protein motif with the T locus. Nature Genetics 7, 383–389.

Legal Presentations

  • Patent Law Year in Review CLE, Fenwick & West, 2014 – 2016.
  • BIO IPCC Spring 2017, “Toto, I’ve a Feeling We’re Not in Texas Anymore . . .” (Panel Presentation).
  • BIO IPCC Spring 2016, “Evolution or Devolution? Developments at the PTAB” (Patent Presentation).